TRPV6 plays a new role in predicting survival of patients with esophageal squamous cell carcinoma
- PDF / 1,527,029 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 70 Downloads / 191 Views
RESEARCH
Open Access
TRPV6 plays a new role in predicting survival of patients with esophageal squamous cell carcinoma Shui-Shen Zhang1,2,3,4†, Xuan Xie5†, Jing Wen1,2,3, Kong-Jia Luo1,2,3, Qian-wen Liu1,2,3, Hong Yang1,2,3, Yi Hu1,2,3* and Jian-Hua Fu1,2,3*
Abstract Background: TRPV6 is over-expressed and promotes the proliferation and invasion in many cancers. The association between the expression of TRPV6 and clinical outcome in esophageal squamous cell carcinoma (ESCC) has not been studied yet. We aim to elucidate the role of TRPV6 in predicting prognosis of patients with ESCC. Methods: In the retrospective study, mRNA level of TRPV6 was examined in patients (N = 174) from Sun Yat-sen University Cancer Center (mRNA cohort) and protein level of TRPV6 was examined in patients (N = 218) from Linzhou Cancer Hospital (protein cohort). Statistical analysis was performed to test the clinical and prognostic significance of TRPV6. Results: TRPV6 was down-regulated in ESCC tissues and cell lines. Patients with downregulation of TRPV6 trended to have a higher rate of advanced pT stage in both mRNA cohort (P = 0.089) and protein cohort (P = 0.073), though not statistically significant. No significant association was observed between TRPV6 expression and disease-specific survival (DSS) in both two cohorts. However, stratified survival analysis based on the gender showed that in mRNA cohort, downregulation of TRPV6 was associated with an unfavorable 3-year DSS in patients with male (47.3 % vs 63.6 %, P = 0.027) and with favorable 3-year DSS in patients with female (66.7 % vs 43.0 %, P = 0.031). The result was confirmed in protein cohort. Male patients with downregulation of TRPV6 had a poor 3-year DSS (20.0 % vs 57.1 %,P < 0.001) while female counterparts showed an enhanced 3-year DSS (56.1 % vs 28.6 %, P = 0.005). Conclusion: TRPV6 is down-regulated in ESCC. As a predictive biomarker, TRPV6 plays a Janus-like role in predicting survival of male and female ESCC patients. Keywords: TRPV6, Esophageal squamous cell carcinoma, Prognosis; survival analysis, Tumor markers
Background Esophageal cancer is one of the most aggressive malignancies worldwide, with more than 480,000 new cases and 400,000 deaths annually. In China, esophageal squamous cell carcinoma (ESCC) ranks 4th among most common causes of death and remains a major burden for public health [1]. Despite advances of surgical techniques and incorporation of new therapeutic approaches, * Correspondence: [email protected]; [email protected] † Equal contributors 1 State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China 2 Guangdong Esophageal Cancer Research Institute, Guangzhou, People’s Republic of China Full list of author information is available at the end of the article
ESCC is still a highly devastating disease with poor prognosis, 5-year overall survival at less than 40 % [2, 3]. Current researches have been focusing on prognostic predictor of ESCC in order to actively adapt therapies for th
Data Loading...
